Aurobindo Pharma Limited

NSE AUROPHARMA.NS

Aurobindo Pharma Limited Goodwill for the year ending March 31, 2024: USD 71.35 M

Aurobindo Pharma Limited Goodwill is USD 71.35 M for the year ending March 31, 2024, a -1.62% change year over year. Goodwill is the value attributed to intangible assets, such as brand reputation or customer relationships, acquired in a business combination.

Aurobindo Pharma Limited Goodwill for the year ending March 31, 2023 was USD 72.52 M, a 15.83% change year over year.
Aurobindo Pharma Limited Goodwill for the year ending March 31, 2022 was USD 62.61 M, a 6.89% change year over year.
Aurobindo Pharma Limited Goodwill for the year ending March 31, 2021 was USD 58.57 M, a -51.81% change year over year.
Aurobindo Pharma Limited Goodwill for the year ending March 31, 2020 was USD 121.55 M, a 1.46% change year over year.

Key data

Date	Goodwill	Total Assets	Current Liabilities	Total Non-Current Liabilities

NSE: AUROPHARMA.NS

Aurobindo Pharma Limited

CEO	Dr. Makkapati Satakarni B.E., M.B.A., Ph.D.
IPO Date	Jan. 15, 1996
Location	India
Headquarters	Galaxy, Plot No. 1
Employees	26,015
Sector	Healthcare
Industries Pharmaceuticals Biotechnology Drugstores & Retail Pharmacies Plastics Vaccines

Description

Aurobindo Pharma Limited engages in the research, development, manufacture, and sale of active pharmaceutical ingredients, generic pharmaceuticals, and related services in India. The company primarily offers oral solids, injectables, and over-the-counter drugs, as well as active pharmaceutical ingredients and finished dosage forms for cardiovascular, central nervous system, gastroenterology, anti-allergies, anti-diabetics, anti-retroviral, antibiotics, dermatology, respiratory, and oncology. It is also involved in the development of a product pipeline in biosimilar and vaccine segments; and custom research and manufacturing activities for the bio-tech and pharmaceutical community. In addition, the company develops and manufactures peptides, as well as biocatalysts for use in the pharmaceutical and chemical industries. Further, it is developing biosimilar, inhalers, transdermal patches, vaccines, topicals, and depot injections. The company also exports its products. It serves multinational companies. The company has an agreement with COVAXX to develop and commercialize COVID-19 Vaccine for India and UNICEF. Aurobindo Pharma Limited was incorporated in 1986 and is headquartered in Hyderabad, India.

Key trends

Past 5 years